IN VITRO AND IN CHEMICO METHODS FOR PREDICTING SKIN SENSITISATION
The Adverse Outcome Pathway for Skin Sensitisation Initiated by Covalent Binding to Proteins
|METHOD||PRINCIPLE OF THE TEST||APPLICABILITY DOMAIN||GHS CATEGORISATION|
|OECD TG 442c: In Chemico Skin Sensitisation – Assays Addressing the Adverse Outcome Pathway Key Event on Covalent Binding to Proteins||The Direct Peptide Reactivity Assay (DPRA) and the Amino Acid Derivative Reactivity Assay (ADRA) are in chemico methods that address the molecular initiating event of the skin sensitisation adverse outcome pathway by quantifying the depletion of synthetic cysteine- or lysine-containing peptides, in the case of the DPRA, and the cysteine derivative N-(2-(1-naphthyl)acetyl)-L-cysteine (NAC) or the lysine derivative α-N-(2-(1-naphthyl)acetyl)-L-lysine (NAL), in the case of the ADRA, following 24-hour exposure to the test chemical using HPLC coupled with a UV detector. Cysteine and lysine peptide or derivative percentage depletion values are calculated and used in prediction models, which are used to discriminate between skin sensitisers and non-sensitisers.||Applicable to chemicals that are soluble in a suitable solvent, e.g. acetonitrile, water, isopropanol, and acetone. Can be used for mixtures of known substances but not of unknown substances. Cannot be used for metals because they are known to react with proteins via mechanisms other than covalent binding, and cannot be used for complex reaction products or biological materials. Chemicals that require enzymatic bioactivation to exert their skin sensitisation potential also cannot be detected.||To support discrimination between skin sensitisers (GHS Cat 1) and non-sensitisers in the context of integrated approaches to testing and assessment (IATA)|
|OECD TG 442d: In Vitro Skin Sensitisation – Assays Addressing the AOP Key Event on Keratinocyte Activation||The KeratinoSens™ and LuSens methods address the second key event in the skin sensitisation AOP using an immortalised adherent cell line derived from human keratinocytes stably transfected with a selectable plasmid. The cell line contains the luciferase gene under the transcriptional control of a constitutive promoter fused with an ARE element from a gene that is known to be upregulated by contact sensitisers – this allows for quantitative measurement (by luminescence detection) of luciferase gene induction.||Applicable to chemicals that are soluble or form a stable dispersion in water or DMSO. Can be used for testing multi-constituent substances and mixtures. Highly cytotoxic test chemicals or test chemicals that interfere with the luciferase enzyme cannot always be reliably assessed.||To support discrimination between skin sensitisers (GHS Cat 1) and non-sensitisers in the context of IATA|
|OECD TG 442e: In Vitro Skin|
Sensitisation Assays Addressing Key Event Activation of Dendritic Cells
|The h-CLAT addresses the third key event in the skin sensitisation AOP, in which immature DCs become activated in response to a sensitiser, after which they move to the lymph nodes and undergo a maturation process; CD86 and CD54 upregulation is a sign of this maturation. This test measures expression of CD86 and CD54 in THP-1 cells (human monocytic leukaemia cell line) following 24-hour exposure to the test chemical, via fl ow cytometry following cell staining with fluorescently labelled antibodies.|
The U-SENS™ method addresses the third key event in the skin sensitisation AOP by quantifying changes in CD86 expression in the human histiocytic lymphoma cell line, U937. CD86 is a cell surface marker associated with the activation of monocytes and DCs in U937 cells following exposure to skin sensitisers. After a 45-hour exposure to the test chemical, CD86 expression is measured via flow cytometry following cell staining with fluorescently labelled antibodies.
The IL-8 Luc assay addresses the third key event in the skin sensitisation AOP using the THP-G8 cell line. THP-G8 cells
are derived from the human acute monocytic leukaemia cell line, THP-1, and contain a luciferase gene under the control of the IL-8 promoter. IL-8 is a cytokine associated with the activation of DCs, and this assay allows for the quantitative measurement of luciferase gene induction as an indicator of IL-8 activity.
|Applicable to chemicals that are soluble or form a stable dispersion in saline, medium, or DMSO. Can be used for testing multi-constituent substances and mixtures. In cases in which a strongly fluorescent test chemical emits at the same wavelength as FITC or as PI, another fluorochrome-tagged antibody should be used.|
Applicable to chemicals that are soluble or form a stable dispersion in an appropriate solvent. Can be used for testing multi-constituent substances and mixtures. Positive results for surfactants should be considered with caution. In cases in which a strongly fluorescent test chemical emits at the same wavelength as FITC or as PI, another fluorochrome-flagged antibody should be used.
Applicable to chemicals that are soluble in X-VIVO™ 15 (Lonza) or other solvents provided there is sufficient scientific rationale. Can be used for testing multiconstituent substances and mixtures. Negative results for respiratory sensitisers should be interpreted with caution. Cannot be used for detergents.
|To support discrimination between skin sensitisers (GHS Cat 1) and non-sensitisers in the context of IATA|
· Organisation for Economic Co-operation and Development. 2016. Guidance document on the reporting of defined approaches and individual information sources to be used within integrated approaches to testing and assessment (IATA) for skin sensitisation. No 256. Series on Testing and Assessment. See also Annex 1 and Annex 2.
· Organisation for Economic Co-operation and Development. 2012. The adverse outcome pathway for skin sensitisation initiated by covalent binding to proteins, No. 168. Series on Testing and Assessment.
Part 1, Part 2.
· U.S. Environmental Protection Agency. 2018. Interim science policy: use of alternative approaches for skin sensitization as a replacement for laboratory animal testing.
· European Chemicals Agency. 2017. Guidance on information requirements and chemical safety assessment. Chapter R.7a: Endpoint specific guidance Version 6.0. See R.7.3.4-R.7.3.7.